What did @sponlinecoaching actually say?
The creator shared their personal TRT protocol: 100 milligrams of testosterone cypionate per week, split into three subcutaneous micro-doses. They also said they use HCG alongside testosterone to "maintain fertility and testicular size." They described the experience as "life-changing" and "worlds apart" from when their testosterone was low, and recommended that viewers who feel symptomatic get tested. They also promoted a discount code for home testosterone testing via DMs.
To be clear, this is someone sharing their own protocol, not prescribing it. That framing matters. But 16,500 viewers watching a specific dose and injection schedule will inevitably treat it as a template, whether the creator intended that or not.
Does the science back this up?
Mostly, yes. The core protocol elements here are clinically reasonable and well-supported. Subcutaneous injection of testosterone cypionate is legitimate, and splitting weekly doses into more frequent smaller injections has real pharmacokinetic logic behind it.
On frequency: injecting testosterone cypionate more often than once weekly produces more stable serum testosterone and estradiol levels, reducing the peaks and troughs associated with weekly injections. A study by Ramasamy et al. (2014, Journal of Urology) found that more frequent dosing better mimics physiological testosterone patterns. Subcutaneous versus intramuscular delivery has been validated too. Engel et al. (2014, Fertility and Sterility) confirmed that subcutaneous testosterone cypionate produces predictable absorption with equivalent bioavailability, and many patients tolerate it better due to smaller needle gauge and reduced injection site discomfort.
On HCG: the evidence base is solid. HCG mimics luteinizing hormone (LH), which drives intratesticular testosterone production and spermatogenesis. Coviello et al. (2005, Journal of Clinical Endocrinology and Metabolism) showed that exogenous testosterone alone suppresses intratesticular testosterone by up to 94%, and that low-dose HCG co-administration largely preserves it. For men who want to maintain fertility or testicular volume on TRT, HCG is a well-established adjunct.
What did they get wrong (or right)?
They got the fundamentals right. The combination of divided-dose subcutaneous testosterone cypionate plus HCG is consistent with current clinical thinking on TRT optimization. Credit where it is due.
What they got wrong, or at least incomplete, is that 100mg weekly is presented without any context about why that dose works for them specifically. Individual response to testosterone therapy varies considerably based on SHBG levels, body composition, aromatization rate, and baseline endogenous production. A 2020 review by Bhasin et al. in the New England Journal of Medicine emphasized that TRT dosing requires individualized titration based on symptom response and follow-up lab monitoring, not a fixed starting point borrowed from someone else's protocol.
The home testing promotion is where things get slippery. A discount code in DMs for a testing service is not inherently wrong, but viewers should know that a single testosterone reading without clinical context, including time of day the sample was taken, SHBG, LH, FSH, and symptoms, is genuinely insufficient to determine whether TRT is appropriate.
What should you actually know?
If you are considering TRT, the single most important thing is not the protocol itself but the diagnosis. Hypogonadism has a clinical definition. The American Urological Association guidelines specify that TRT should only be initiated in men with consistently low serum testosterone confirmed on at least two morning measurements, combined with symptoms attributable to deficiency. "Feeling low" is a starting point for investigation, not a diagnosis.
Beyond that, TRT is not without real trade-offs. Exogenous testosterone suppresses the hypothalamic-pituitary-gonadal axis, meaning natural production drops significantly or stops. Fertility is affected, which is exactly why the creator uses HCG. Hematocrit rises on TRT, increasing cardiovascular risk if unmonitored. A 2023 randomized trial by Lincoff et al. (New England Journal of Medicine, the TRAVERSE trial) found no significant increase in major cardiovascular events in TRT-treated men with hypogonadism, but it also confirmed elevated rates of pulmonary embolism and atrial fibrillation, risks worth knowing before you start.
The bottom line: this creator is describing a legitimate, clinically coherent protocol for themselves. That is not the same as recommending it for you. Get a proper workup with a licensed clinician before touching any of this.